alphavestcapital.com

42.9K posts

alphavestcapital.com banner
alphavestcapital.com

alphavestcapital.com

@alphavestcap

40+ Years of Financial Expertise

Radnor,Pennsylvania شامل ہوئے Ekim 2014
3K فالونگ1.9K فالوورز
alphavestcapital.com
alphavestcapital.com@alphavestcap·
@alphavestcap $nwbo x.com/ATLnsider/stat… x.com/ATLnsider/stat… x.com/ATLnsider/stat… x.com/alphavestcap/s… x.com/alphavestcap/s… x.com/alphavestcap/s… x.com/alphavestcap/s… x.com/alphavestcap/s… Dr. Brian Czerniecki, colleague & collaborator with Dr. Pawel Kalinski continue to have success treating metastatic breast cancer with their Type 1 polarized alpha dendritic cell vaccine. This IP complements $NWBO #DCVax very well: instagram.com/reel/DXMYVXmBL… ·Mar 10Show moreFollowers50Posts8916Boards Moderated0Alias Born05/27/2011📷sukus sukus Re: pgsd post# 817184 Monday, March 09, 2026 12:27:15 PM For those who don't know LMD's prognosis is very bleak. Estimated only 2 months to 4 months of life. Recurring GBM is very$nwbo@alphavestcapaacrjournals.orgAbstract PD13-07: A transcriptomic analysis of a first in human phase I trial of intrathecal...AbstractBackground:. Leptomeningeal disease (LMD) is a devastating complication of breast cancer (BC) and occurs in ˜5% of patients and has a poor prognosis. The CSF of patients with LMD have an...alphavestcapital.com@alphavestcap·Mar 10Show moreLatest Pawel Kalinski co-authored article with interesting Gemini AI Analysis of relevance and synergy: Poster Spotlight Abstracts| February 17 2026 Abstract PD13-07: A transcriptomic analysis of a first in human phase I trial of intrathecal dendritic$nwbo@alphavestcapaacrjournals.orgAbstract PD13-07: A transcriptomic analysis of a first in human phase I trial of intrathecal...AbstractBackground:. Leptomeningeal disease (LMD) is a devastating complication of breast cancer (BC) and occurs in ˜5% of patients and has a poor prognosis. The CSF of patients with LMD have an...alphavestcapital.com@alphavestcap·Sep 22, 2025Show moreSkyLimit2022 Re: Investor082 post# 789381 Monday, September 22, 2025 PM Post# of 789402 Aligning a CNPV application with the MAA decision could be strategically effective timing.zero82, ”4 odd years ago” 📷 Actually, Orbis is more of a relevant$nwbo@alphavestcapalphavestcapital.com@alphavestcap·Aug 18, 2025Show moreThose trials conducted at H. Lee Moffitt Cancer Center and Research Institute must share one thing in common. They have to use $NWBO's 'Coca-Cola formula' to pulse DCs$nwbo@alphavestcaphttps://x.com/d_stock07734/status/1957450357094912106 $nwbo@alphavestcaphttps://x.com/d_stock07734/status/19574503570949121@d_stock07734Quoted_stock@d_stock07734·Aug 18, 2025Those trials conducted at H. Lee Moffitt Cancer Center and Research Institute must share one thing in common. They have to use $NWBO's 'Coca-Cola formula' to pulse DCs with peptides derived from certain antigens. The efficacy of the treatment tells the truth! PCR: Pathologic x.com/MC17595091/sta…
alphavestcapital.com@alphavestcap

$nwbo @alphavestcap Dr. Brian Czerniecki(Moffitt Cancer Center) and Dr. Pawel Kalinski (formerly UPMC, now Roswell Park) are leading experts in immunotherapy for breast cancer. x.com/search?q=pawel… x.com/alphavestcap/s… x.com/peter_brit/sta… x.com/alphavestcap/s… These are results for kalinski czernicki breast cancer moffat roswell upmc Search instead for kalinski czercnicki breat cacer mioffit roswell upmc AI Overview Dr. Brian Czerniecki(Moffitt Cancer Center) and Dr. Pawel Kalinski (formerly UPMC, now Roswell Park) are leading experts in immunotherapy for breast cancer. They focus on dendritic cell vaccines, immune system activation, and novel therapies to combat advanced or resistant breast cancer, with notable trials in metastatic triple-negative and brain-metastatic disease.📷Roswell Park Comprehensive Cancer Center +4Key Experts & Institutions:Dr. Brian Czerniecki (Moffitt Cancer Center): As Chair of Breast Oncology at Moffitt, he specializes in immune-based therapies, particularly dendritic cell vaccines designed to prevent breast cancer invasion and metastasis. His work has included trials that use personalized vaccines to train immune cells against tumor markers. Dr. Pawel Kalinski (Roswell Park Comprehensive Cancer Center): Formerly of UPMC Hillman Cancer Center, Dr. Kalinski is Vice Chair of Translational Research Development at Roswell Park. He focuses on modifying tumor environments to make them more receptive to immunotherapy, including using agents like rintatolimod and interferon in combination with dendritic cell therapies. Key Focus Areas: Both researchers are active in developing novel combinations of immunotherapy (checkpoint inhibitors, dendritic vaccines) to treat metastatic triple-negative breast cancer (mTNBC) and breast cancer that has spread to the brain.📷Roswell Park Comprehensive Cancer Center +9Key Collaborative or Institutional Work:Moffitt: Focuses on antigen-presenting cells to target breast cancer and research into preventing dormant cancer cells from waking. Roswell Park/UPMC: Dr. Kalinski's move from UPMC to Roswell Park marked a focus on enhancing "killer" T-cell function and developing NCI-funded immunotherapies, including trials tackling brain metastases.📷Roswell Park Comprehensive Cancer Center +4Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy EffortMar 31, 2020 — The trials are not yet underway, but Dr. Kalinski and his team expect to open all five studies by year-end 2021. The studies will ...📷Roswell Park Comprehensive Cancer Center📷 Moffitt Launches Innovative Trial for Brain-Metastatic Breast CancerOct 1, 2019 — He is leading a phase 2 clinical trial for brain-metastatic breast cancer patients. The trial is funded by a four-year, $8.3 milli...📷Moffitt📷 Brian Czerniecki, MD, PhD - Breast OncologyMar 8, 2018 — my name is Brian Zerniki i'm the chair of the department of breast oncology at Moffett Cancer Center. we use an advanced. process ...📷📷YouTube·Moffitt Cancer Center📷51sShow all Dive deeper in AI Mode This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Novel Immunotherapy Approach at Roswell Park Shows ... 📷 Roswell Park Comprehensive Cancer Center roswellpark.org › newsroom › 202311-nove... Nov 14, 2023 — Drs. Shipra Gandhi and Pawel Kalinski will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for metastatic ...Read more Missing: czernicki moffat upmc Moffitt Study Identifies Immune Response That May Stop ... 📷 Moffitt moffitt.org › newsroom › news-releases Feb 17, 2025 — A new Moffitt Cancer Center study has identified a specific immune response that may prevent the spread of breast cancer cells within the body.Read more Pawel Kalinski M.D., Ph.D. - Department of Immunology 📷 University of Pittsburgh immunology.pitt.edu › people › pawel-kali... He has extensive experience building and leading Team Science programs within P01s (ovarian, breast, melanoma, colon, SPOREs (ovarian and melanoma), and MPI ...Read more Missing: czernicki | Show results with: czernicki Moffitt Launches Innovative Trial for Brain-Metastatic Breast ... 📷 Moffitt moffitt.org › endeavor › archive › moffitt-... Oct 1, 2019 — A dendritic cell vaccine developed by Czerniecki in collaboration with Pawel Kalinski, M.D., Ph.D. of Roswell Park Comprehensive Cancer Center ...Read more Missing: upmc | Show results with: upmc Sponsored result Main Line Health Breast Cancer - Expert Surgeons & Oncologists 📷 Main Line Health pages.mainlinehealth.org › main-line › breast-cancer 📷 📷 Accepting new patients. Discover how Main Line Health can help find the options you need. Our nurse navigators guide you through expert breast... Our Providers · Breast Cancer Specialists · Schedule a Consultation Hide sponsored result Dr. Czerniecki on Treatment Options for Patients With ... 📷 OncLive onclive.com › OncLive TV Jul 15, 2020 — Brian Czerniecki, MD, PhD, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases. Pawel Kalinski's Post 📷 LinkedIn · Pawel Kalinski 30+ reactions · 1 year ago ... Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer roswellpark.org · 37 6 ...Read more Missing: czernicki moffat People also ask Is Moffitt good for breast cancer? What type of breast cancer has the worst prognosis? What foods should I avoid after breast cancer? What stage is a 7 cm breast tumor? Moffit Cancer Center SCOUT MD Experience: Brian J ... 📷 YouTube · Merit Medical 80+ views · 5 months ago 📷 4:00 Moffit Cancer Center SCOUT MD Experience: Brian J Czerniecki, MD, PhD ... My First Breast Cancer Symptoms: "I Knew I Had Cancer" | Christine's ... Post Gazette: 'It's really dramatic how far things have come' 📷 St. Clair Health stclair.org › St. Clair Info › Media Center Oct 29, 2023 — New guidelines released this year say that women of average risk for breast cancer should begin getting mammograms at age 40, and should get them every other ...Read more Study Shows Targeted Therapy Needed for Metastatic ... 📷 UPMC upmc.com › ... › lee breast ca mets UPMC Cancer researchers find molecular changes in primary breast tumors in patients with brain metastases leading to changes in therapy. Missing: kalinski czernicki moffat roswell Pawel Kalinski - Cancer Immunology and Immunotherapy 📷 UPMC hillmanresearch.upmc.edu › ... › Pawel Kalinski Pawel Kalinski,. Pawel Kalinski. Contact Information. microscope Cancer Immunology and Immunotherapy. Email kalinskip@upmc.edu.Read more People also search for

English
0
0
0
225
alphavestcapital.com
alphavestcapital.com@alphavestcap·
@alphavestcap Two researchers from UPenn and Boston University just published a paper that should be uncomfortable reading for every CEO automating their workforce right now. The argument is straightforward. Every company replacing workers with AI is also eliminating its own future customers. Laid off workers stop spending. Enough of them stop spending and nobody can afford to buy anything. The companies that fired everyone end up selling into an economy with no purchasing power left. Every executive can see this. The math is not complicated. But here is why nobody stops. If you do not automate, your competitor does. They cut costs, lower prices, take your market share, and you collapse anyway. So every company automates knowing it is collectively destructive because the alternative is dying alone while everyone else survives. The researchers proved this is a Prisoner's Dilemma playing out in real time. The numbers are already moving. Block cut nearly half its 10,000 employees this year. Jack Dorsey said AI made those roles unnecessary and that within the next year the majority of companies will reach the same conclusion. Salesforce replaced 4,000 customer support agents with AI. Goldman Sachs deployed a coding tool that lets one engineer do the work of five. Over 100,000 tech workers were laid off in 2025 and AI was cited as the primary driver in more than half those cases. 80% of US workers hold jobs with tasks susceptible to AI automation. The researchers tested every proposed solution. Universal basic income does not change a single company's incentive to automate. Capital income taxes adjust profit levels but not the per-task decision to replace a human. Collective bargaining cannot hold because automating is always the dominant strategy. They also identified what they call a Red Queen effect. Better AI does not solve the problem, it accelerates it. Every company chases faster automation to gain market share over rivals but at the end everyone has automated equally, the gains cancel out, and the only thing left is more destroyed demand. The one thing the math says could work is a Pigouvian automation tax. A per-task charge that forces companies to account for the demand they destroy each time they replace a worker. The conclusion is that this is not a transfer of wealth from workers to owners. Both sides lose. Workers lose income. Companies lose customers. It is a deadweight loss with no market mechanism to stop it on its own.
English
0
0
0
44
alphavestcapital.com
alphavestcapital.com@alphavestcap·
$nwbo @alphavestcap 8K-4/7/26: "In connection with the acquisition, the Company obtained from the Securities and Exchange Commission, pursuant to its authority under Rule 3-13 under Regulation S-X, a waiver from the requirements of Rule 3-05 and Article 11 of Regulation S-X to provide certain financial statements of Advent under Rule 3-05 of Regulation S-X and pro forma financial information relating to the acquisition. Accordingly, the Company will not provide such pro forma information under Item 9.01 of Form 8-K." sec.gov/ix?doc=/Archiv… sec.gov/ix?doc=/Archiv… x.com/alphavestcap/s… x.com/alphavestcap/s… x.com/alphavestcap/s… sec.gov/edgar/browse/?… x.com/alphavestcap/s… sec.gov/ix?doc=/Archiv… sec.gov/Archives/edgar… sec.gov/Archives/edgar… …te.company-information.service.gov.uk/company/087177…. (2024 Advent annual report)
alphavestcapital.com@alphavestcap

$nwbo @alphavestcap "Equity contribution from acquisition of Advent $ 35 million" x.com/alphavestcap/s…

English
0
0
3
604

دریافت کریں

@elonmusk @BarackObama @taylorswift13 @cristiano @BillGates @NASA @nikifrancismediavine @katyperry